Mood Disorder Questionnaire (MDQ)

Abstract

The Mood Disorder Questionnaire (MDQ) is a widely utilized, brief self-report screening instrument developed by Robert M. A. Hirschfeld and colleagues in 2000 to identify individuals likely to meet criteria for bipolar spectrum disorders, specifically Bipolar I, Bipolar II, and Bipolar Disorder Not Otherwise Specified (NOS). Designed to address the pervasive clinical problem of diagnostic delay and misdiagnosis of bipolar disorder as unipolar major depressive disorder, the MDQ captures lifetime occurrences of hypomanic and manic symptoms derived from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The core instrument comprises three primary sections: (1) 13 dichotomous (yes/no) items assessing lifetime manic/hypomanic behavioral and psychological symptoms, (2) a single item assessing symptom co-occurrence (synchronicity), and (3) an ordinal item evaluating the functional impairment caused by these symptoms across occupational, interpersonal, and legal domains (graded as No Problem, Minor Problem, Moderate Problem, or Serious Problem). Clinical scoring criteria require an affirmative response to at least seven of the 13 symptom items, an affirmative response for symptom co-occurrence, and a rating of moderate or serious functional impairment. Extensive psychometric evaluations demonstrate sound internal consistency, with Cronbach’s alpha ranging from 0.79 to 0.90 across diverse psychiatric and community samples. In psychiatric outpatient settings, the instrument exhibits robust diagnostic accuracy (sensitivity: 0.73; specificity: 0.90), though sensitivity decreases in community samples (0.28) and primary care settings (0.58), accompanied by elevated specificity (0.93–0.97). This article provides a comprehensive academic analysis of the MDQ’s historical purpose, theoretical foundations, psychometric validity, factor structure, scoring algorithms, and full scale items.

Keywords

Mood Disorder Questionnaire, MDQ, bipolar disorder, bipolar spectrum disorder, hypomania, mania, psychiatric screening, diagnostic delay, psychometrics, affective disorders

Authors

The Mood Disorder Questionnaire was authored by a multidisciplinary team of prominent psychiatric researchers, psychometricians, and clinical experts:

• Robert M. A. Hirschfeld, M.D. — Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
• Janet B. W. Williams, D.S.W. — Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, USA.
• Robert L. Spitzer, M.D. — Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, New York, USA.
• Joseph R. Calabrese, M.D. — Department of Psychiatry, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio, USA.
• Laurie Flynn — National Alliance on Mental Illness (NAMI), Arlington, Virginia, USA.
• Paul E. Keck Jr., M.D. — Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
• Lydia Lewis — Depression and Bipolar Support Alliance (DBSA), Chicago, Illinois, USA.
• Susan L. McElroy, M.D. — Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
• Robert M. Post, M.D. — Biological Psychiatry Branch, National Institute of Mental Health (NIMH), Bethesda, Maryland, USA.
• Daniel J. Rapport, M.D. — Department of Psychiatry, Case Western Reserve University, Cleveland, Ohio, USA.
• James M. Russell, M.D. — Department of Psychiatry and Behavioral Sciences, University of Texas Medical Branch, Galveston, Texas, USA.
• Gary S. Sachs, M.D. — Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• John Zajecka, M.D. — Department of Psychiatry, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois, USA.

Purpose

The primary clinical and epidemiological purpose of the MDQ is to deliver a rapid, accessible, self-administered screening mechanism that detects a lifetime history of hypomanic or manic episodes among adult patients. Accurate identification of bipolar disorder has long been an obstinate challenge in psychiatric medicine. Epidemiological investigations have repeatedly highlighted that individuals with bipolar disorder frequently endure a diagnostic latency ranging from 8 to 12 years between the initial presentation of mood symptoms and the receipt of an accurate diagnosis (Lish et al., 1994). Patients with bipolar disorder are overwhelmingly prone to seeking professional psychiatric care during depressive episodes rather than hypomanic phases, because hypomania is often perceived as productive, ego-syntonic, or pleasurable. Consequently, clinicians frequently diagnose these patients with major depressive disorder (unipolar depression).

This systematic misdiagnosis introduces profound clinical hazards. The prescription of antidepressant monotherapy to an unrecognized bipolar patient carries substantial risks of inducing treatment-emergent affective switches into mania, promoting rapid cycling, and accelerating mood episode destabilization. Moreover, delaying mood-stabilizing or second-generation antipsychotic interventions substantially exacerbates psychosocial morbidity, functional impairment, substance misuse comorbidity, and the long-term risk of suicide attempts. The MDQ was specifically conceptualized to intercept this trajectory across primary care clinics, community mental health facilities, and specialized psychiatric practices, alerting clinicians to the necessity of comprehensive, semi-structured psychiatric evaluations.

In addition to routine clinical screening, the MDQ serves critical functions in psychopharmacological research, molecular genetics studies, and community health epidemiology. In randomized controlled trials (RCTs) investigating therapeutics for unipolar depression, the MDQ is commonly employed to eliminate individuals with latent or subthreshold bipolar spectrum conditions, thereby securing sample homogeneity. In epidemiological cohorts, the MDQ enables researchers to estimate the population prevalence of bipolar spectrum manifestations outside traditional inpatient psychiatric settings.

Psychological Construct

The MDQ assesses the overarching construct of the bipolar spectrum, which encompasses Bipolar I Disorder, Bipolar II Disorder, and Cyclothymic Disorder, as operationalized by the DSM-IV and subsequently reaffirmed in the DSM-5. The core psychopathological construct comprises three tightly interconnected clinical dimensions:

1. Lifetime Manic/Hypomanic Symptom Cluster

This dimension operationalizes the affective, cognitive, somatic, and behavioral markers characterizing expansive, elevated, or irritable mood episodes:

• Elevated/Expansive/Irritable Affect: Experiencing periods where one is hyper, euphoric, or exceptionally irritable to the point of initiating verbal altercations or arguments.
• Grandiosity and Inflated Self-Esteem: Feelings of profoundly heightened self-confidence, ungrounded self-assurance, or omnipotence.
• Decreased Need for Sleep: Sleeping noticeably fewer hours than normal without experiencing daytime fatigue or sleep deficit distress.
• Pressured Speech: Talking excessively, feeling internal pressure to keep talking, or speaking at a markedly accelerated cadence.
• Flight of Ideas and Racing Thoughts: Subjective experiences of thoughts accelerating beyond control, jumping rapidly from topic to topic.
• Distractibility: Marked inability to filter external stimuli, resulting in severe disruption of concentration and goal persistence.
• Psychomotor Agitation and Goal-Directed Energy: Escalations in physiological energy, physical restlessness, or undertaking multiple concurrent projects.
• Disinhibition, Hedonism, and High-Risk Behavior: Engaging in impulsive, reckless behaviors with elevated potential for painful or catastrophic outcomes, such as uncharacteristic sexual encounters, reckless driving, or problematic spending sprees.

2. Symptom Synchronicity (Co-Occurrence)

A cardinal diagnostic tenet of affective disorder psychopathology is that true manic and hypomanic states do not reflect transient, isolated personality traits or sporadic, fragmented symptoms. Rather, they emerge as a syndromal cluster wherein multiple behavioral, affective, and cognitive deviations manifest simultaneously within the same bounded temporal timeframe. The MDQ directly evaluates whether two or more confirmed symptoms clustered together during a distinct episode of time.

3. Functional Impairment

In psychometric psychopathology, symptoms alone do not constitute a psychiatric disorder unless they elicit significant functional interference across vocational, interpersonal, familial, or legal spheres. The MDQ measures this construct through a graded self-assessment of the adverse consequences induced by the identified symptom cluster, allowing clinicians to distinguish between benign, adaptive periods of creative hyper-productivity and clinically meaningful hypomanic/manic impairment.

Theoretical Framework

The structural design of the MDQ is rooted in the neo-Kraepelinian categorical classification framework that informed the creation of the modern DSM operational criteria. Emil Kraepelin initially synthesized melancholic depression and mania into a single unitary nosology titled “manic-depressive insanity.” However, mid-20th-century psychiatric nosology bifurcated affective conditions into distinct unipolar and bipolar entities. Subsequent conceptual models—most notably articulated by Hagop Akiskal and Jules Angst—postulated the existence of a broad bipolar spectrum spanning a continuous gradient from classic Bipolar I mania to subtle cyclothymic affective temperaments, recurrent brief hypomania, and antidepressant-induced hypomania.

Hirschfeld and colleagues adopted a pragmatic psychometric compromise between categorical diagnostic boundaries and spectrum conceptualizations. The MDQ leverages the explicit criteria sets established in DSM-IV for manic episodes (Criterion A through Criterion E). It requires an unequivocal mood change (“not your usual self”), a constellation of concurrent behavioral disturbances (Criterion B), episodic clustering, and observable functional disruption. By requiring concurrent endorsement of energy escalation, behavioral disinhibition, and cognitive acceleration, the scale reflects the psychobiological hyperactivity characteristic of hyperdopaminergic and dysregulated frontolimbic network states during bipolar episodes.

Validity

Extensive psychometric investigations have established the validity of the MDQ across diverse clinical, non-clinical, and cross-cultural cohorts:

Criterion and Diagnostic Validity

In the original validation investigation conducted by Hirschfeld et al. (2000), the MDQ was administered to 198 psychiatric outpatients across five specialized tertiary mood disorder centers who subsequently underwent blinded, independent diagnostic evaluations utilizing the Structured Clinical Interview for DSM-IV (SCID). Using the standard scoring threshold (affirmation of $ge 7$ symptoms, co-occurrence, and moderate-to-serious impairment):

• Sensitivity: 0.73 (correctly identifying 73% of patients with confirmed bipolar spectrum disorders).
• Specificity: 0.90 (correctly excluding 90% of individuals with unipolar depression or other non-bipolar conditions).

Subsequent investigations, however, illuminated substantial performance disparities across clinical subtypes and settings. In a critical evaluation of depressed psychiatric outpatients, Miller et al. (2004) identified a global sensitivity of 0.58 and specificity of 0.67. Importantly, diagnostic sensitivity proved substantially superior for Bipolar I disorder (~0.69 to 0.80) than for Bipolar II disorder (~0.30 to 0.40). Because Bipolar II hypomania, by definition, does not involve severe functional impairment, requiring “moderate or serious problem” on Item 3 leads to frequent false negatives in Bipolar II populations. Consequently, many researchers advocate eliminating or attenuating the Item 3 criterion when screening specifically for Bipolar II or cyclothymic conditions.

Population and Primary Care Performance

When evaluated in large-scale community and primary care environments, the MDQ demonstrates distinct psychometric profiles. In a nationwide community epidemiological sample ($N = 85,358$), Hirschfeld et al. (2003) noted that the standard cutoff yielded a sensitivity of only 0.28 against SCID diagnoses, coupled with an exceptional specificity of 0.97. In family practice and general medical settings, Hirschfeld et al. (2005) identified a sensitivity of 0.58 and a specificity of 0.93. The marked decline in sensitivity within community samples mirrors the lower baseline prevalence of bipolar spectrum disorders in unselected populations, underscoring that the MDQ functions reliably as a risk indicator rather than a stand-alone diagnostic instrument.

Convergent and Discriminant Validity

Convergent validity is reinforced by strong correlations with other validated bipolar scales, including the Hypomania Checklist-32 (HCL-32) and the Bipolar Spectrum Diagnostic Scale (BSDS). Discriminant validity, while generally robust against major depressive disorder, encounters notable challenges when differentiating bipolar spectrum disorders from borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD). Patients with BPD frequently score above threshold on the MDQ due to overlapping phenomenologies involving affective instability, impulsivity, reckless spending, and interpersonal conflicts, generating elevated false-positive rates in populations with high personality pathology.

Reliability

The MDQ possesses highly satisfactory reliability indices across various linguistic adaptations and healthcare settings:

• Internal Consistency: In the initial psychiatric validation cohort, Hirschfeld et al. (2000) reported a Cronbach’s alpha coefficient of 0.79 for the 13 symptom items. Subsequent investigations across international clinical samples have yielded alpha values between 0.82 and 0.90 (e.g., Isometsä et al., 2003; Wang et al., 2015), demonstrating high internal homogeneity among the item pool.
• Test-Retest Reliability: Hirschfeld et al. (2000) administered the MDQ over an average retest window of 2.7 to 4 weeks, yielding an excellent test-retest reliability index (Cohen’s kappa, $kappa = 0.81$, $p < 0.001$). Intra-class correlation coefficients (ICC) across translated versions consistently exceed 0.80, confirming temporal stability when assessing lifetime psychiatric phenotypes.
• Item-Total Correlations: Standard item-total correlation coefficients for the 13 symptom questions consistently range from 0.42 to 0.68, confirming that each individual behavioral marker contributes meaningfully to the latent construct of mania/hypomania.

Factor Analysis

Extensive exploratory factor analyses (EFA) and confirmatory factor analyses (CFA) conducted across diverse clinical and non-clinical populations have generally rejected a strict unidimensional model in favor of well-defined multi-factor solutions:

Two-Factor vs. Three-Factor Models

Numerous psychometric structural analyses identify a robust two-factor or three-factor latent structure underlying the 13 symptom items:

• Factor 1: Energy and Positive Activation (Energized/Expansive Mood): Comprises items reflecting grandiosity/self-confidence (Item 3), reduced sleep requirement (Item 4), accelerated speech (Item 5), racing thoughts (Item 6), heightened energy (Item 8), elevated activity levels (Item 9), and enhanced sociability (Item 10). Items on this factor reflect classical activated hypomania.
• Factor 2: Impulsivity and Behavioral Dysregulation (Irritability/Risk-Taking): Encompasses items measuring extreme irritability and fighting (Item 2), excessive/reckless spending (Item 13), high-risk or foolish behaviors (Item 12), hypersexuality (Item 11), distractibility (Item 7), and social disruption (Item 1). This factor accounts for substantial diagnostic variance in clinical distress and functional impairment.

In structural equation modeling (SEM), confirmatory factor analyses frequently reveal that a bifactor model—comprising a general bipolar vulnerability factor alongside orthogonal specific factors (energy activation vs. impulsive disruption)—demonstrates superior goodness-of-fit indices (Comparative Fit Index $[CFI] > 0.95$, Tucker-Lewis Index $[TLI] > 0.94$, Root Mean Square Error of Approximation $[RMSEA] < 0.05$) compared to an undifferentiated single-factor structure.

Instrument / Measurement Tool

The MDQ is structured as a brief paper-and-pencil or digital self-report questionnaire taking approximately 5 to 10 minutes to complete. The architecture of the tool is detailed below:

• Assessment Type: Self-report psychiatric screening instrument (clinical and epidemiological).
• Target Population: Adults aged 18 and older (adapted versions exist for adolescents, e.g., MDQ-A).
• Total Number of Sections/Items: 3 primary functional sections (Question 1 containing 13 sub-items, Question 2 containing 1 item, Question 3 containing 1 item) plus 2 supplementary clinical history queries (Questions 4 and 5).
• Response Scales:
  • Question 1 (13 items): Dichotomous (Yes / No).
  • Question 2 (Co-occurrence): Dichotomous (Yes / No).
  • Question 3 (Functional Impairment): 4-point categorical scale (No Problem, Minor Problem, Moderate Problem, Serious Problem).
  • Questions 4 & 5 (Family History & Prior Diagnosis): Dichotomous (Yes / No).
• Standard Diagnostic Scoring Rules: A positive screen for bipolar spectrum disorder requires ALL THREE of the following clinical criteria:
  1. Endorsement of 7 or more ‘Yes’ responses out of the 13 items in Question 1.
  2. Endorsement of ‘Yes’ to Question 2 (confirming symptom co-occurrence in time).
  3. Selecting either ‘Moderate Problem’ or ‘Serious Problem’ on Question 3.
• Alternative/Modified Scoring Rules: To maximize sensitivity for Bipolar II disorder, modified scoring algorithms drop the Question 3 impairment requirement to ‘Minor Problem’ or eliminate it entirely, and adjust the Question 1 cutoff to 5 or 6 endorsed items.

Permissions & Fee and Test Year

The Mood Disorder Questionnaire was formally published in 2000 by Robert M. A. Hirschfeld and colleagues under the copyright of the authors and the University of Texas Medical Branch. In partnership with organizations such as the Depression and Bipolar Support Alliance (DBSA), the MDQ was made widely accessible without cost to clinicians and academic researchers for routine clinical screening and non-profit scientific investigation. While freely downloadable for non-commercial clinical care and scholarly inquiries, commercial deployments, institutional software integrations, or pharmaceutical trial applications may require licensing agreements and formal permission from the original copyright holders.

References

• Hirschfeld, R. M. A., Williams, J. B. W., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., Russell, J. M., Sachs, G. S., & Zajecka, J. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: The Mood Disorder Questionnaire. American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873
• Hirschfeld, R. M. A. (2002). The Mood Disorder Questionnaire: A simple, patient-rated screening for bipolar disorder. Primary Care Companion to The Journal of Clinical Psychiatry, 4(1), 9–11. https://doi.org/10.4088/PCC.v04n0104
• Hirschfeld, R. M. A., Holzer, C., Calabrese, J. R., Weissman, M. M., Reed, M., Davies, M., Frye, M. A., McElroy, S. L., Lewis, L., & Hazlett, L. (2003). Validity of the Mood Disorder Questionnaire: A general population study. American Journal of Psychiatry, 160(1), 178–180. https://doi.org/10.1176/appi.ajp.160.1.178
• Hirschfeld, R. M. A., Cass, A. R., Holt, D. C. L., & Carlson, C. A. (2005). Screening for bipolar disorder in patients treated for depression in a family medicine clinic. The Journal of the American Board of Family Practice, 18(4), 233–239. https://doi.org/10.3122/jabfm.18.4.233
• Isometsä, E., Suominen, K., & Mantere, O. (2003). The Mood Disorder Questionnaire—Finnish version. Nordic Journal of Psychiatry, 57(4), 314–318.
• Lish, J. D., Dime-Meenan, S., Whybrow, P. C., Price, R. A., & Hirschfeld, R. M. A. (1994). The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. Journal of Affective Disorders, 31(4), 281–294. https://doi.org/10.1016/0165-0327(94)90104-X
• Miller, C. J., Klugman, J., Berv, D. A., Rosenquist, K. J., & Ghaemi, S. N. (2004). Sensitivity and specificity of the Mood Disorder Questionnaire for detecting bipolar disorder. Journal of Affective Disorders, 81(2), 167–171. https://doi.org/10.1016/S0165-0327(03)00155-2
• Wang, H. R., Woo, Y. S., Ahn, H. S., Fountoulakis, K. N., Sloan, N. P., & Bahk, W. M. (2015). The validity of the Mood Disorder Questionnaire for screening bipolar disorder: A meta-analysis. Depression and Anxiety, 32(7), 527–538. https://doi.org/10.1002/da.22375
• Zimmerman, M., Galione, J. N., Ruggero, C. J., Chelminski, I., Young, D., Dalrymple, K., & McGlinchey, J. B. (2008). Screening for bipolar disorder and finding borderline personality disorder. The Journal of Clinical Psychiatry, 69(8), 1214–1217. https://doi.org/10.4088/JCP.v69n0804

13. Items of the Scale (Questionnaire)